CRL - Charles River Laboratories International Stock Price, Fair Value and News

$187.97+1.87 (+1.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CRL Price Action

Last 7 days

-9.0%

Last 30 days

-3.6%

Last 90 days

-6.6%

Trailing 12 Months

-2.2%

CRL RSI Chart

CRL Valuation

Market Cap

9.6B

Price/Earnings (Trailing)

22.73

Price/Sales (Trailing)

2.37

EV/EBITDA

11.69

Price/Free Cashflow

12.07

CRL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

-1.64%

Rev. Growth (Qtr)

-1.59%

CRL Earnings

Earnings (TTM)

422.8M

Earnings Growth (Yr)

-21.41%

Earnings Growth (Qtr)

-27%

CRL Profitability

EBT Margin

15.34%

Return on Equity

11.16%

Return on Assets

5.28%

Free Cashflow Yield

8.28%

CRL Investor Care

Buy Backs (1Y)

0.31%

Diluted EPS (TTM)

8.01

CRL Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.1B	4.1B	4.1B	0
2023	4.1B	4.2B	4.2B	4.1B
2022	3.6B	3.7B	3.8B	4.0B
2021	3.0B	3.3B	3.4B	3.5B
2020	2.7B	2.7B	2.8B	2.9B
2019	2.4B	2.4B	2.5B	2.6B
2018	1.9B	2.0B	2.1B	2.3B
2017	1.8B	1.8B	1.8B	1.9B
2016	1.4B	1.5B	1.6B	1.7B
2015	1.3B	1.3B	1.3B	1.4B
2014	1.2B	1.2B	1.3B	1.3B
2013	1.1B	1.1B	1.2B	1.2B
2012	1.1B	1.1B	1.1B	1.1B
2011	1.1B	1.1B	1.1B	1.1B
2010	1.2B	1.1B	1.1B	1.1B
2009	0	0	0	1.2B

Get all data in R, Python etc through our Historical Stock Data APIs

About Charles River Laboratories International

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CEO	Mr. James C. Foster J.D.
WEBSITE	criver.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	20000

Charles River Laboratories International Frequently Asked Questions

What is the ticker symbol for Charles River Laboratories International? What does CRL stand for in stocks?

CRL is the stock ticker symbol of Charles River Laboratories International. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Charles River Laboratories International (CRL)?

As of Wed Nov 20 2024, market cap of Charles River Laboratories International is 9.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers.

Is Charles River Laboratories International a good stock to buy?

The fair value guage provides a quick view whether CRL is over valued or under valued. Whether Charles River Laboratories International is cheap or expensive depends on the assumptions which impact Charles River Laboratories International's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRL.

What is Charles River Laboratories International's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, CRL's PE ratio (Price to Earnings) is 22.73 and Price to Sales (PS) ratio is 2.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Charles River Laboratories International's stock?

In the past 10 years, Charles River Laboratories International has provided 0.114 (multiply by 100 for percentage) rate of return.